Financial Performance - The company's operating revenue for Q3 2021 was ¥286,832,808.31, representing a year-on-year increase of 14.58%[5] - The net profit attributable to shareholders for the same period was ¥34,094,417.15, with a slight increase of 0.56% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥31,592,979.36, reflecting a year-on-year growth of 9.45%[5] - Total operating revenue for the first three quarters of 2021 reached RMB 806,313,048.29, an increase of 26.5% compared to RMB 637,354,410.66 in the same period of 2020[21] - Net profit for Q3 2021 reached CNY 103.26 million, up 13.7% from CNY 90.79 million in Q3 2020[23] - Operating profit for Q3 2021 was CNY 123.28 million, a 24.5% increase from CNY 98.90 million in Q3 2020[22] Assets and Liabilities - The total assets at the end of the reporting period reached ¥1,695,993,122.06, an increase of 84.12% compared to the end of the previous year[6] - As of September 30, 2021, total assets amounted to RMB 1,695,993,122.06, significantly up from RMB 921,121,087.27 at the end of 2020, reflecting a growth of 84.2%[20] - Current assets totaled RMB 1,172,287,398.49, compared to RMB 422,075,464.32 at the end of 2020, indicating a substantial increase of 178.5%[18] - Total liabilities were reported at RMB 274,027,481.29, a slight increase from RMB 258,071,288.86, reflecting a growth of 6.5%[20] Shareholder Equity - The equity attributable to shareholders increased by 114.46% to ¥1,421,965,640.77, primarily due to successful fundraising from the company's listing in July[11] - Shareholders' equity rose to RMB 1,421,965,640.77, compared to RMB 663,049,798.41 at the end of 2020, indicating a growth of 114.5%[20] Cash Flow - The cash flow from operating activities for the year-to-date was ¥79,019,840.49, showing a significant increase of 58.80%[6] - Cash flow from operating activities for the first nine months of 2021 was CNY 79.02 million, compared to CNY 49.76 million in the same period of 2020, representing a 58.7% increase[27] - The company reported a net cash flow from financing activities of CNY 653.79 million in the first nine months of 2021, compared to no inflow in the same period of 2020[27] Research and Development - Research and development expenses totaled ¥13,613,352.30, which is a decrease of 28.03% compared to the same period last year[6] - Research and development expenses for Q3 2021 were CNY 46.41 million, a decrease of 9.5% from CNY 51.44 million in Q3 2020[22] Government Subsidies - The company received government subsidies amounting to ¥2,496,801.28 during the reporting period, contributing to its non-recurring gains[10] Shareholder Information - The company reported a total of 8,876 common shareholders at the end of the reporting period[14] - The number of shares held by the top ten unrestricted shareholders reflects a diverse ownership structure, with no significant related party transactions noted[15] Investment Activities - Cash inflow from investment activities in the first nine months of 2021 was CNY 188.00 million, significantly higher than CNY 94.09 million in the same period of 2020[27] - Cash outflow from investment activities for the first nine months of 2021 was CNY 783.79 million, compared to CNY 163.07 million in the same period of 2020, indicating a substantial increase in investment[27] Other Financial Metrics - The basic earnings per share for Q3 2021 was ¥0.34, down 17.97% year-on-year[6] - Basic and diluted earnings per share for Q3 2021 were both CNY 1.10, compared to CNY 1.29 in Q3 2020[24] - Tax expenses for Q3 2021 amounted to CNY 17.12 million, an increase of 45.5% from CNY 11.73 million in Q3 2020[23]
华纳药厂(688799) - 2021 Q3 - 季度财报